Abstract
Peripheral lymphocyte counts were performed on 41 patients with advanced breast cancer, before starting treatment with oestrogens or androgens. Patients were seen at monthly intervals, and the response to treatment was independently assessed, using the criteria of the British Breast Group. In the patients treated with oestrogens and androgens, the successful responders were found to have significantly higher pre-treatment peripheral lymphocyte counts than the intermediate responders and failures. It is suggested that pre-treatment peripheral lymphocyte counts may have a prognostic value in assessing potential response to hormone therapy in patients with breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Franks, C., Williams, Y. Prognostic value of peripheral lymphocyte count in hormone therapy of advanced breast cancer. Br J Cancer 34, 641–644 (1976). https://doi.org/10.1038/bjc.1976.225
Issue Date:
DOI: https://doi.org/10.1038/bjc.1976.225
This article is cited by
-
Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis
Breast Cancer Research and Treatment (1985)
